Cerecor Inc. (NASDAQ:CERC) major shareholder Armistice Capital Master Fund purchased 113,649 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was bought at an average cost of $0.73 per share, with a total value of $82,963.77. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Thursday, August 24th, Armistice Capital Master Fund purchased 120,435 shares of Cerecor stock. The stock was bought at an average cost of $0.66 per share, with a total value of $79,487.10.
  • On Monday, August 21st, Armistice Capital Master Fund purchased 219,792 shares of Cerecor stock. The stock was bought at an average cost of $0.60 per share, with a total value of $131,875.20.
  • On Wednesday, August 16th, Armistice Capital Master Fund purchased 954,228 shares of Cerecor stock. The stock was bought at an average cost of $0.61 per share, with a total value of $582,079.08.

Shares of Cerecor Inc. (CERC) opened at 0.732 on Friday. The company has a 50-day moving average of $0.70 and a 200 day moving average of $0.67. Cerecor Inc. has a one year low of $0.34 and a one year high of $5.60. The stock’s market cap is $19.07 million.

Cerecor (NASDAQ:CERC) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. The firm had revenue of $0.16 million during the quarter. On average, equities analysts forecast that Cerecor Inc. will post ($1.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Buying: Cerecor Inc. (CERC) Major Shareholder Buys $82,963.77 in Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/insider-buying-cerecor-inc-cerc-major-shareholder-buys-82963-77-in-stock/1535968.html.

About Cerecor

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.